# Unity Biotechnology Inc. (UBX)

Source: https://www.quantisnow.com/company/UBX
Generated: 2026-11-04T19:13:55.075Z

- Ticker: UBX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- Website: unitybiotechnology.com

## About

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

## Latest UBX news and filings

- 2025-07-22 20:07 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Unity Biotechnology Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-unity-biotechnology-inc-6128260)
- 2025-07-22 20:05 UTC [SEC Form 8-K] [Unity Biotechnology Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/unity-biotechnology-inc-filed-sec-form-8-k-amendments-to-articles-6128239)
- 2025-07-17 20:06 UTC [SEC Form 3] [SEC Form 3 filed by new insider Jalbert Craig R.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-jalbert-craig-r-6123753)
- 2025-06-30 12:00 UTC [SEC Form 8-K] [Unity Biotechnology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/unity-biotechnology-inc-filed-sec-form-8-k-notice-of-delisting-6102929)
- 2025-06-20 20:10 UTC [SEC Form 8-K] [Unity Biotechnology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/unity-biotechnology-inc-filed-sec-form-8-k-notice-of-delisting-6093746)
- 2025-05-27 13:09 UTC [Analyst Downgrade] [Unity Biotechnology downgraded by H.C. Wainwright with a new price target](https://www.quantisnow.com/insight/unity-biotechnology-downgraded-by-hc-wainwright-with-a-new-price-6058420)
- 2025-05-16 15:17 UTC [Analyst Downgrade] [Unity Biotechnology downgraded by Mizuho with a new price target](https://www.quantisnow.com/insight/unity-biotechnology-downgraded-by-mizuho-with-a-new-price-target-6044707)
- 2025-05-15 20:31 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Unity Biotechnology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-unity-biotechnology-inc-6043013)
- 2025-05-05 12:00 UTC [SEC Form 8-K] [Unity Biotechnology Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/unity-biotechnology-inc-filed-sec-form-8-k-costs-associated-with-6017130)
- 2025-05-01 12:00 UTC [Conference Announcement] [UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting](https://www.quantisnow.com/insight/unity-biotechnology-to-present-at-the-arvo-2025-annual-meeting-6012212)
- 2025-04-23 12:00 UTC [UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME](https://www.quantisnow.com/insight/unity-biotechnology-announces-publication-in-nejm-evidence-highlighting-the-potential-5997367)
- 2025-04-22 20:31 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Unity Biotechnology Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-unity-biotechnology-inc-5996648)
- 2025-04-22 20:30 UTC [SEC Form 8-K] [Unity Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/unity-biotechnology-inc-filed-sec-form-8-k-results-of-operations-5996607)
- 2025-04-22 20:29 UTC [UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates](https://www.quantisnow.com/insight/unity-biotechnology-inc-reports-first-quarter-2025-financial-results-and-5996582)
- 2025-04-11 20:10 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Unity Biotechnology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-unity-biotechnology-inc-5985574)
- 2025-04-04 20:10 UTC [SEC Form 8-K] [Unity Biotechnology Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/unity-biotechnology-inc-filed-sec-form-8-k-leadership-update-5977918)
- 2025-04-03 20:17 UTC [SEC Form 4] [CLO and Head of Ops Nguyen Alexander Hieu sold $18,388 worth of shares (17,852 units at $1.03), decreasing direct ownership by 27% to 48,753 units (SEC Form 4)](https://www.quantisnow.com/insight/clo-and-head-of-ops-nguyen-alexander-hieu-sold-18388-5975623)
- 2025-04-03 20:16 UTC [SEC Form 4] [CFO & Head of Corp. Dev. Sullivan Lynne Marie sold $22,523 worth of shares (21,867 units at $1.03), decreasing direct ownership by 18% to 98,905 units (SEC Form 4)](https://www.quantisnow.com/insight/cfo-head-of-corp-dev-sullivan-lynne-marie-sold-22523-5975602)
- 2025-04-03 20:16 UTC [SEC Form 144] [SEC Form 144 filed by Unity Biotechnology Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-unity-biotechnology-inc-5975595)
- 2025-04-03 20:15 UTC [SEC Form 4] [Chief Executive Officer Ghosh Anirvan sold $99,701 worth of shares (96,797 units at $1.03), decreasing direct ownership by 39% to 153,454 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-ghosh-anirvan-sold-99701-worth-of-shares-5975541)
- 2025-03-31 20:19 UTC [SEC Form 4] [CLO and Head of Ops Nguyen Alexander Hieu sold $2,267 worth of shares (1,954 units at $1.16) and was granted 44,000 shares, increasing direct ownership by 171% to 66,605 units (SEC Form 4)](https://www.quantisnow.com/insight/clo-and-head-of-ops-nguyen-alexander-hieu-sold-2267-5967279)
- 2025-03-31 20:16 UTC [SEC Form 4] [CFO & Head of Corp. Dev. Sullivan Lynne Marie was granted 65,000 shares, increasing direct ownership by 117% to 120,772 units (SEC Form 4)](https://www.quantisnow.com/insight/cfo-head-of-corp-dev-sullivan-lynne-marie-was-granted-5967224)
- 2025-03-31 20:15 UTC [SEC Form 4] [Chief Executive Officer Ghosh Anirvan was granted 175,000 shares, increasing direct ownership by 233% to 250,251 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-ghosh-anirvan-was-granted-175000-shares-increasing-5967174)
- 2025-03-24 11:01 UTC [Earnings Date] [UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema](https://www.quantisnow.com/insight/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-5956870)
- 2025-03-24 11:00 UTC [SEC Form 8-K] [Unity Biotechnology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/unity-biotechnology-inc-filed-sec-form-8-k-other-events-financial-5956867)
- 2025-03-23 20:00 UTC [Conference Announcement] [UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025](https://www.quantisnow.com/insight/unity-biotechnology-to-host-virtual-investor-event-to-discuss-24--5956707)
- 2025-03-17 20:13 UTC [SEC Form 8-K] [Unity Biotechnology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/unity-biotechnology-inc-filed-sec-form-8-k-notice-of-delisting-5947282)
- 2025-03-10 12:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Hashad Yehia](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hashad-yehia-5935009)
- 2025-03-10 12:02 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hashad Yehia](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hashad-yehia-5935004)
- 2025-03-10 12:00 UTC [SEC Form 8-K] [Unity Biotechnology Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/unity-biotechnology-inc-filed-sec-form-8-k-leadership-update-other-5934982)
- 2025-03-10 12:00 UTC [Leadership Update] [UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors](https://www.quantisnow.com/insight/unity-biotechnology-appoints-industry-leader-and-ophthalmology-expert-yehia-hashad-5934923)
- 2025-03-07 21:40 UTC [SEC Form S-8] [SEC Form S-8 filed by Unity Biotechnology Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-unity-biotechnology-inc-5933805)
- 2025-03-07 21:31 UTC [SEC Form 10-K] [SEC Form 10-K filed by Unity Biotechnology Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-unity-biotechnology-inc-5933741)
- 2025-03-07 21:30 UTC [SEC Form 8-K] [Unity Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/unity-biotechnology-inc-filed-sec-form-8-k-results-of-operations-5933665)
- 2025-03-07 21:30 UTC [UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates](https://www.quantisnow.com/insight/unity-biotechnology-inc-reports-fourth-quarter-and-full-year-2024-5933650)
- 2025-02-05 21:35 UTC [SEC Form 4] [CFO & Head of Corp. Dev. Sullivan Lynne Marie sold $341 worth of shares (153 units at $2.23), decreasing direct ownership by 0.27% to 55,772 units (SEC Form 4)](https://www.quantisnow.com/insight/cfo-head-of-corp-dev-sullivan-lynne-marie-sold-341-5873403)
- 2025-02-05 21:33 UTC [SEC Form 4] [CLO and Head of Ops Nguyen Alexander Hieu sold $366 worth of shares (164 units at $2.23), decreasing direct ownership by 0.66% to 24,559 units (SEC Form 4)](https://www.quantisnow.com/insight/clo-and-head-of-ops-nguyen-alexander-hieu-sold-366-5873380)
- 2025-02-05 21:30 UTC [SEC Form 4] [Chief Executive Officer Ghosh Anirvan sold $1,432 worth of shares (642 units at $2.23), decreasing direct ownership by 0.85% to 75,251 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-ghosh-anirvan-sold-1432-worth-of-shares-5873311)
- 2025-01-23 21:07 UTC [SEC Form 4] [SEC Form 4 filed by CLO and Head of Ops Nguyen Alexander Hieu](https://www.quantisnow.com/insight/sec-form-4-filed-by-clo-and-head-of-ops-5855281)
- 2025-01-23 21:05 UTC [SEC Form 4] [SEC Form 4 filed by CFO & Head of Corp. Dev. Sullivan Lynne Marie](https://www.quantisnow.com/insight/sec-form-4-filed-by-cfo-head-of-corp-dev-5855247)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/UBX
- Earnings history: https://www.quantisnow.com/earnings/UBX
- Dividend history: https://www.quantisnow.com/dividends/UBX
- Insider transactions: https://www.quantisnow.com/insiders/UBX
- Options chain: https://www.quantisnow.com/options/UBX
- SEC 8-K filings only: https://www.quantisnow.com/company/UBX/8-k
- RSS and alerts for UBX: https://www.quantisnow.com/docs/rss-feeds.md